---
title: "Rexulti (brexpiprazole) in major depressive disorder: Indication questions"
description: "Indication questions on Rexulti (brexpiprazole) in major depressive disorder, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Eligibility. Questions: What is Rexulti approved for in major depressive disorder? Rexulti and partial response: how is partial response to an antidepressant defined? 2 questions quoted from 3 sources."
canonical: "https://www.evicenter.com/medical-information/rexulti--major-depressive-disorder/indication"
published: "2026-11-13T03:43:41-05:00"
modified: "2026-11-14T01:54:55-05:00"
---

# Rexulti (brexpiprazole) in major depressive disorder: Indication questions

Manufacturer: Otsuka America Pharmaceutical, Inc.; Lundbeck  
Prescribing information: [Rexulti](https://www.otsuka-us.com/media/static/Rexulti-PI.pdf)

Indication questions that apply to every indication of Rexulti are on [Rexulti (brexpiprazole), all indications: Indication](https://www.evicenter.com/medical-information/rexulti/indication).

## Indication

<a id="rexulti-indication"></a>

### What is Rexulti approved for in major depressive disorder?

> “Adjunctive treatment to antidepressants for major depressive disorder (MDD) in adults”

Source: [REXULTI: Prescribing information, page 3, captured 2026-11-13](https://www.otsuka-us.com/media/static/Rexulti-PI.pdf#page=3)

> “REXULTI is indicated for use as an adjunctive therapy to antidepressants for the treatment of major depressive disorder 
> (MDD) in adults”

Source: [REXULTI: BROCHURE, page 1, captured 2026-11-13](https://www.rexultihcp.com/mdd/content/dam/rexulti/hcp/websites/com/live-assets/pdfs/mdd-dosing-guide.pdf#page=1)

Note: The second passage is from the MDD dosing guide that the dosing page of the Rexulti HCP site links.

## Eligibility

<a id="rexulti-partial-response-definition"></a>

### Rexulti and partial response: how is partial response to an antidepressant defined?

> “Partial Response has been defined as a 25-50% reduction from baseline in depression scale scores<sup>4,c</sup>”

Source: [REXULTI: REXULTI® (brexpiprazole) | MDD | Partial Response, captured 2026-11-13](https://www.rexultihcp.com/mdd/partial-response#:~:text=Partial%20Response%20has%20been%20defined,from%20baseline%20in%20depression%20scale)

> “The HAM-D has been the metric of choice for measuring depression in research settings. Other scales such as the MADRS and the Inventory for Depressive Symptomatology have also been used.<sup>4</sup>”

Source: [REXULTI: REXULTI® (brexpiprazole) | MDD | Partial Response, captured 2026-11-13](https://www.rexultihcp.com/mdd/partial-response#:~:text=The%20HAM%2DD%20has%20been%20the,Depressive%20Symptomatology%20have%20also%20been)

## Related pages
- [Medical information: Rexulti (brexpiprazole): Major depressive disorder](https://www.evicenter.com/medical-information/rexulti--major-depressive-disorder)
- [Clinical trials](https://www.evicenter.com/medical-information/rexulti--major-depressive-disorder/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/rexulti--major-depressive-disorder/safety)
- [Specific populations](https://www.evicenter.com/medical-information/rexulti--major-depressive-disorder/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/rexulti--major-depressive-disorder/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/rexulti--major-depressive-disorder/dosing-and-administration)
- [Access and coverage](https://www.evicenter.com/medical-information/rexulti--major-depressive-disorder/access-and-coverage)
